tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

NewAmsterdam Pharma’s Promising Phase 3 Alzheimer’s Trial Results

Story Highlights
  • NewAmsterdam Pharma focuses on oral medicines for cardiovascular disease with high LDL-C.
  • Obicetrapib significantly reduced Alzheimer’s biomarkers, suggesting dual health benefits.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
NewAmsterdam Pharma’s Promising Phase 3 Alzheimer’s Trial Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from NewAmsterdam Pharma Company ( (NAMS) ) is now available.

On July 30, 2025, NewAmsterdam Pharma announced promising results from its Phase 3 BROADWAY clinical trial, which evaluated the effects of obicetrapib on Alzheimer’s disease biomarkers. The trial showed that obicetrapib significantly reduced levels of plasma p-tau217, a key biomarker of Alzheimer’s pathology, especially in ApoE4 carriers, a group at heightened risk for the disease. These findings suggest that obicetrapib could offer a novel approach to Alzheimer’s prevention while also providing cardiovascular benefits, positioning the company as a potential leader in addressing both neurodegenerative and cardiovascular diseases.

The most recent analyst rating on (NAMS) stock is a Hold with a $23.60 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.

Spark’s Take on NAMS Stock

According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.

The overall stock score reflects the strong technical and corporate event outlook, suggesting significant future potential. However, the company’s current lack of profitability and overbought technical indicators temper the overall optimism.

To see Spark’s full report on NAMS stock, click here.

More about NewAmsterdam Pharma Company

NewAmsterdam Pharma Company N.V. is a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (LDL-C), particularly for those for whom existing therapies are not sufficiently effective or well-tolerated.

Average Trading Volume: 852,219

Technical Sentiment Signal: Strong Buy

Current Market Cap: $2.63B

Find detailed analytics on NAMS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1